Golo

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Golo sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials none currently recruiting 2 completed later-stage tilt upper half by trial count

Golo: 2 sponsored US clinical trials, none currently recruiting.

Golo sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus Type II, with 1 trials.

Mid-pack sponsor footprint

Golo is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

2 total, page 1 of 1

COMPLETED Phase 3

Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity

NCT03842501
COMPLETED NA

GOLO Open-Label Pilot 1

NCT03478202

Phase Distribution

PhaseTrial count
Phase 3 1

Therapeutic Areas

Diabetes Mellitus Type II 1
Obesity 1

How the Golo archive is shaped

2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Diabetes Mellitus Type II (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Golo: archived-pipeline peers nationwide

Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Golo sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Golo1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Golo sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Golo sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Golo page

2 registered trials is a research-attention snapshot, not an endorsement of Golo or any single study.

  • None of Golo's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Diabetes Mellitus Type II is the condition Golo studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus Type II trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Golo pipeline card: 2 registered trials from official public datasets.Report a data error.